# Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Canonical: https://abierto.us/opportunities/ht940224q9202

- Solicitation number: HT9402-24-Q-9202
- Notice type: Solicitation
- Status: Closed. Deadline was February 15, 2024 at 1:00 PM EST
- Department: Department of Defense
- Agency: Defense Health Agency (Dha)
- Contracting office: Defense Health Agency (HT9402)
- NAICS: 325412 Pharmaceutical Preparation Manufacturing
- Product or service code: 6505 Drugs and Biologicals
- Place of performance: San Antonio, Texas
- County: Bexar County (FIPS 48029). https://abierto.us/counties/bexar-county-tx-48029
- City: San Antonio. https://abierto.us/cities/san-antonio-tx-4865000
- First posted: January 25, 2024
- Last posted: January 31, 2024
- SAM.gov: https://sam.gov/workspace/contract/opp/b64db76ac74f46e3912e891cc7b3cd84/view

## Description

The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents.

The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF).

Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.

**P&T COMMITTEE MEETING:**

**May 2024:** The following newly approved drugs will be reviewed: a. Agamree - Corticosteroids - Immune Modulators - NA b. Fabhalta - Hematological Agents - NA c. Iwilfin - Oncological Agents – NA d. Vevye - Ophthalmic - Dry Eye e. Wainua - Neurological Agents Miscellaneous – NA f. Zilbrysq - Neurological Agents Miscellaneous – NA g. Zituvio - Diabetes Non-Insulin - Dipeptidyl Peptidase 4 (DPP-4) Inhibitors h. Zoryve - Psoriasis Agents - NA The RFQ, including UF BPA and UF ADP appendices are attached here in.

The instructions, important deadlines, and points of contact are in document, RFQ HT9402-24-Q-9202. Pre-quotation teleconference is on January 31, 2024, details are stated in Part 2.5. Pre-proposalteleconference, contact RFQ Point of Contact (POC) for agenda and dial-in information. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC (stated in Part 2.3), no later than the date stated in Part 2.4.

## Publications

- January 25, 2024: Solicitation, due February 15, 2024 at 1:00 PM EST. Notice 4f69de5973a840b5a028404a4c16ce72. https://sam.gov/workspace/contract/opp/4f69de5973a840b5a028404a4c16ce72/view
- January 31, 2024: Solicitation, due February 15, 2024 at 1:00 PM EST. Notice 43d4f93a02cb41249d4cd5556e0b147a. https://sam.gov/workspace/contract/opp/43d4f93a02cb41249d4cd5556e0b147a/view
- January 31, 2024: Solicitation, due February 15, 2024 at 1:00 PM EST. Notice b64db76ac74f46e3912e891cc7b3cd84. https://sam.gov/workspace/contract/opp/b64db76ac74f46e3912e891cc7b3cd84/view

## Points of contact

- Tracy Banks, tracy.e.banks2.civ@health.mil
- Julia Trang, julia.n.trang.civ@health.mil

---
Source: SAM.gov Contract Opportunities bulk extract. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/ht940224q9202.